Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment

Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment

Bibliographic Details
Main Authors: David Parker, Marc-Antoine Belaud-Rotureau
Format: Article
Language:English
Published: SAGE Publishing 2014-12-01
Series:Clinical Medicine Insights: Oncology
Online Access:http://www.la-press.com/micro-cost-analysis-of-alk-rearrangement-testing-by-fish-to-determine--article-a4554
id doaj-8d6518edaf1f4126a35fe96de636f075
record_format Article
spelling doaj-8d6518edaf1f4126a35fe96de636f0752020-11-25T02:53:52ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492014-12-01201481451524554Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and TreatmentDavid ParkerMarc-Antoine Belaud-Rotureauhttp://www.la-press.com/micro-cost-analysis-of-alk-rearrangement-testing-by-fish-to-determine--article-a4554
collection DOAJ
language English
format Article
sources DOAJ
author David Parker
Marc-Antoine Belaud-Rotureau
spellingShingle David Parker
Marc-Antoine Belaud-Rotureau
Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
Clinical Medicine Insights: Oncology
author_facet David Parker
Marc-Antoine Belaud-Rotureau
author_sort David Parker
title Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
title_short Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
title_full Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
title_fullStr Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
title_full_unstemmed Micro-cost Analysis of ALK Rearrangement Testing by FISH to Determine Eligibility for Crizotinib Therapy in NSCLC: Implications for Cost Effectiveness of Testing and Treatment
title_sort micro-cost analysis of alk rearrangement testing by fish to determine eligibility for crizotinib therapy in nsclc: implications for cost effectiveness of testing and treatment
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2014-12-01
url http://www.la-press.com/micro-cost-analysis-of-alk-rearrangement-testing-by-fish-to-determine--article-a4554
work_keys_str_mv AT davidparker microcostanalysisofalkrearrangementtestingbyfishtodetermineeligibilityforcrizotinibtherapyinnsclcimplicationsforcosteffectivenessoftestingandtreatment
AT marcantoinebelaudrotureau microcostanalysisofalkrearrangementtestingbyfishtodetermineeligibilityforcrizotinibtherapyinnsclcimplicationsforcosteffectivenessoftestingandtreatment
_version_ 1724723867855880192

Similar Items